In active MS lesions, CCL2 was shown to be expressed by monocyte/macrophage cells and astroglia whereas CCL5 production was observed predominantly in non-immune cells, that is, astrocytes and endothelial components 26,27. Here, CCL2 is linked to myeloid sarcoma.